Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study (2024)

Abstract

©
This work is licensed under a Creative Commons Attribution 4.0 International License.

Article metrics loading...

http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.25.2300585

Full text loading...

References

1. World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic 2023.Geneva: WHO. [Accessed: 19 Nov 2023]. Available from: https://www.who.int/europe/emergencies/situations/covid-19.

2. Cavaleri M, Enzmann H, Straus S, Cooke E. The European Medicines Agency’s EU conditional marketing authorisations for COVID-19 vaccines. Lancet. 2021;397(10272):355-7. https://doi.org/10.1016/S0140-6736(21)00085-4PMID: 33453149

3. Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;12(12):CD015477. https://doi.org/10.1002/14651858.CD015477PMID: 36473651

4. Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):173. https://doi.org/10.1186/s12916-021-02059-5PMID: 34315454

5. Rolfes L, Härmark L, Kant A, van Balveren L, Hilgersom W, van Hunsel F. COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes. Vaccine. 2022;40(7):970-6. https://doi.org/10.1016/j.vaccine.2022.01.013PMID: 35067381

6. European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Annex 1 - Definitions (Rev 4) - EMA/876333/2011 Rev 4. London: EMA; 2017. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf.

7. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4(1):39. https://doi.org/10.1038/s41541-019-0132-6PMID: 31583123

8. Sprent J, King C. COVID-19 vaccine side effects: The positives about feeling bad. Sci Immunol. 2021;6(60):eabj9256. https://doi.org/10.1126/sciimmunol.abj9256PMID: 34158390

9. Oyebanji OA, Wilson B, Keresztesy D, Carias L, Wilk D, Payne M, et al. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? Aging Clin Exp Res. 2021;33(11):3151-60. https://doi.org/10.1007/s40520-021-01987-9PMID: 34652783

10. Hwang YH, Song KH, Choi Y, Go S, Choi SJ, Jung J, et al. Can reactogenicity predict immunogenicity after COVID-19 vaccination? Korean J Intern Med (Korean Assoc Intern Med). 2021;36(6):1486-91. https://doi.org/10.3904/kjim.2021.210PMID: 34038996

11. Hermann EA, Lee B, Balte PP, Xanthakis V, Kirkpatrick BD, Cushman M, et al. Association of symptoms after COVID-19 vaccination with anti-SARS-CoV-2 antibody response in the Framingham Heart Study. JAMA Netw Open. 2022;5(10):e2237908. https://doi.org/10.1001/jamanetworkopen.2022.37908PMID: 36269359

12. Uwamino Y, Kurafuji T, Sato Y, Tomita Y, Shibata A, Tanabe A, et al. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff. Vaccine. 2022;40(7):1019-25. https://doi.org/10.1016/j.vaccine.2022.01.002PMID: 35033389

13. Bauernfeind S, Salzberger B, Hitzenbichler F, Scigala K, Einhauser S, Wagner R, et al. Association between reactogenicity and immunogenicity after vaccination with BNT162b2. Vaccines (Basel). 2021;9(10):1089. https://doi.org/10.3390/vaccines9101089PMID: 34696197

14. Held J, Esse J, Tascilar K, Steininger P, Schober K, Irrgang P, et al. Reactogenicity correlates only weakly with humoral immunogenicity after COVID-19 vaccination with BNT162b2 mRNA (Comirnaty). Vaccines (Basel). 2021;9(10):1063. https://doi.org/10.3390/vaccines9101063PMID: 34696171

15. Ogrič M, Žigon P, Podovšovnik E, Lakota K, Sodin-Semrl S, Rotar Ž, et al. Differences in SARS-CoV-2-Specific antibody responses after the first, second, and third doses of BNT162b2 in naïve and previously infected individuals: a 1-year observational study in healthcare professionals. Front Immunol. 2022;13:876533. https://doi.org/10.3389/fimmu.2022.876533PMID: 35711413

16. Huiberts AJ, Kooijman MN, Melker HEd, Hahne SJ, Grobbee DE, Hoeve C, et al. Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO). Research Square. Preprint. 2022 . https://doi.org/10.21203/rs.3.rs-1645696/v1

17. Pluijmaekers A, Melker Hd. The National Immunisation Programme in the Netherlands. Surveillance and developments in 2021-2022. Bilthoven: National Institute for Public Health and the Environment; 2022. Available from: https://www.rivm.nl/bibliotheek/rapporten/2022-0042.pdf

18. Højsgaard S, Halekoh U, Yan J. The R Package geepack for Generalized Estimating Equations. J Stat Softw. 2006;15(2):1-11. https://doi.org/10.18637/jss.v015.i02

19. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. Available from: https://www.R-project.org

20. Wickham HAM, Bryan J, Chang WML, François R, Grolemund GHA, Henry L, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4(43):1686. https://doi.org/10.21105/joss.01686

21. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021;4(12):e2140364. https://doi.org/10.1001/jamanetworkopen.2021.40364PMID: 34935921

22. Tsai R, Hervey J, Hoffman K, Wood J, Johnson J, Deighton D, et al. COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: cross-sectional, internet-based survey. JMIR Public Health Surveill. 2022;8(1):e29872. https://doi.org/10.2196/29872PMID: 34709184

23. Salter SM, Li D, Trentino K, Nissen L, Lee K, Orlemann K, et al. Safety of four COVID-19 vaccines across primary doses 1, 2, 3 and booster: a prospective cohort study of Australian community pharmacy vaccinations. Vaccines (Basel). 2022;10(12):2017. https://doi.org/10.3390/vaccines10122017PMID: 36560426

24. European Medicines Agency (EMA). Comirnaty: EPAR- product information. Amsterdam: EMA; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf.

25. European Medicines Agency (EMA). Spikevax (previously COVID-19 Vaccine Moderna): EPAR - product information. Amsterdam: EMA; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf.

26. European Medicines Agency (EMA). AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 2021. Amsterdam: EMA. [Accessed: 27 Feb 2024]. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood-platelets

27. Braun E, Horowitz NA, Leiba R, Weissman A, Mekel M, Shachor-Meyouhas Y, et al. Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses. Clin Microbiol Infect. 2022;28(12):1644-8. https://doi.org/10.1016/j.cmi.2022.07.002PMID: 35843565

28. Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022;28(5):1072-82. https://doi.org/10.1038/s41591-022-01721-6PMID: 35165453

29. Orlandi C, Stefanetti G, Barocci S, Buffi G, Diotallevi A, Rocchi E, et al. Comparing heterologous and hom*ologous COVID-19 vaccination: a longitudinal study of antibody decay. Viruses. 2023;15(5):1162. https://doi.org/10.3390/v15051162PMID: 37243247

30. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947-53. https://doi.org/10.1038/s41562-021-01122-8PMID: 33972767

31. Azzolini E, Canziani LM, Voza A, Desai A, Pepys J, De Santis M, et al. Short-term adverse events and antibody response to the BNT162b2 SARS-CoV-2 vaccine in 4156 health care professionals. Vaccines (Basel). 2022;10(3):439. https://doi.org/10.3390/vaccines10030439PMID: 35335071

32. Cheng A, Hsieh MJ, Chang SY, Ieong SM, Cheng CY, Sheng WH, et al. Correlation of adverse effects and antibody responses following hom*ologous and heterologous COVID19 prime-boost vaccinations. J Formos Med Assoc. 2023;122(5):384-92. https://doi.org/10.1016/j.jfma.2022.12.002PMID: 36564299

33. Hamada H, Futamura M, Ito H, Yamamoto R, Yata K, Iwatani Y, et al. Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study. Vaccine. 2023;41(9):1632-7. https://doi.org/10.1016/j.vaccine.2023.01.050PMID: 36737319

34. den Hartog G, Vos ERA, van den Hoogen LL, van Boven M, Schepp RM, Smits G, et al. Persistence of antibodies to severe acute respiratory syndrome coronavirus 2 in relation to symptoms in a nationwide prospective study. Clin Infect Dis. 2021;73(12):2155-62. https://doi.org/10.1093/cid/ciab172PMID: 33624751

35. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron. N Engl J Med. 2022;386(14):1377-80. https://doi.org/10.1056/NEJMc2202542PMID: 35297591

36. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131-41. https://doi.org/10.1016/S1473-3099(22)00271-7PMID: 35550261

37. Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med. 2022;28(11):2388-97. https://doi.org/10.1038/s41591-022-02031-7PMID: 36202997

38. Kobashi Y, Shimazu Y, Kawamura T, Nishikawa Y, Omata F, Kaneko Y, et al. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. PLoS One. 2022;17(6):e0269917. https://doi.org/10.1371/journal.pone.0269917PMID: 35687563

39. Bettinger JA, Irvine MA, Shulha HP, Valiquette L, Muller MP, Vanderkooi OG, et al. Adverse events following immunization with mRNA and viral vector vaccines in individuals with previous SARS-CoV-2 infection from the Canadian National Vaccine Safety Network. Clin Infect Dis. 2022;76(6):1088-102. https://doi.org/10.1093/cid/ciac852PMID: 36310514

Data & Media loading...